Evidence map›Paper›PMID 39331271›Full record

ArticleDiscover oncology2024

Examining the influence of tumor-infiltrating macrophages on breast cancer outcomes and identifying relevant genes for diagnostic purposes.

Xiaoyun Zhang, Cheng Peng, Xuesong Xiong, Jianchun Lian

Abstract read
In one paragraph

Article in Discover oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Xiaoyun ZhangDepartment of Medical Laboratory, The Affiliated Huaian No.1 People's Hospital of Nanjing Medical University, Huanghe West Road 1, Huaian, Jiangsu, China.
Cheng PengDepartment of Medical Laboratory, The Affiliated Huaian No.1 People's Hospital of Nanjing Medical University, Huanghe West Road 1, Huaian, Jiangsu, China.
Xuesong XiongDepartment of Medical Laboratory, The Fifth People's Hospital of Huai'an, Huaian, Jiangsu, China.
Jianchun LianDepartment of Medical Laboratory, The Affiliated Huaian No.1 People's Hospital of Nanjing Medical University, Huanghe West Road 1, Huaian, Jiangsu, China. ljc19861222@163.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveThe purpose of this research was to investigate how different types of immune cells impact the outlook of individuals with breast cancer, as well as identify the essential genes associated with immune cell subtype enrichment.

methodsThe Cancer Genome Atlas (TCGA) database and Gene Expression Omnibus (GEO) database were used to obtain global transcriptome sequencing data sets of breast tissue. The study utilized the CIBERSORT algorithm to determine the presence of 22 different types of immune cells in both breast cancer tissue and normal breast tissue.Immune cell infiltration content was utilized to conduct univariate COX analysis in order to identify risk factors linked to breast cancer prognosis.

resultsUnivariate COX analysis indicates that Macrophages M1 and B cells naive are beneficial factors for the outlook of individuals with breast cancer (P < 0.05), while Macrophages M2 and Monocytes are detrimental factors for the prognosis of breast cancer patients (P < 0.05). The high infiltration group of macrophage M2 had a poorer prognosis compared to the low infiltration group (P < 0.001); Conversely, the high infiltration group of macrophage M1 had a better prognosis than the low infiltration group (P = 0.002).

conclusionThe study provided an overview of immune cell infiltration in breast cancer tissues, identifying macrophage M1 and macrophage M2 as potential factors in breast cancer development and progression. Additionally, genes associated with macrophage phenotype were analyzed, offering insights into macrophage polarization mechanisms.

Indexed as

Breast cancerImmune cellsPrognosis

Identifiers

PMID39331271
PMCPMC11436547

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.